Skip to main content

Connective tissue diseases

Myositis

11-08-2022 | Guidelines | News

Updated European guidance on vaccination issued for pediatric rheumatology patients

Click through for more details on the EULAR recommendations

27-05-2022 | Myositis | News

Pain and opioid use common in myositis

Nearly all patients with myositis report current or past pain, which is often treated with opioids, shows a survey by the patient-led advocacy organization Myositis Support and Understanding.

Omega-3 pill and glass of water

01-03-2022 | Myositis | News

Mixed results for branched-chain amino acids in polymyositis, dermatomyositis

Branched-chain amino acid supplementation has no impact on muscle strength or clinical response in people with polymyositis or dermatomyositis but may improve dynamic repetitive muscle function, Japanese study data show.

21-02-2022 | Cardiovascular disease | News

EULAR releases recommendations on CV risk management in RMD patients

EULAR has issued recommendations for managing cardiovascular risk in people with antiphospholipid syndrome, gout, mixed connective tissue disease, myositis, Sjögren’s syndrome, systemic lupus erythematosus, systemic sclerosis, or vasculitis.

Rituximab and rheumatology practice in the COVID-19 era

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

07-11-2021 | ACR 2021 | Conference coverage | News

Belimumab, arimoclomol disappoint in myositis trials

Findings from two randomized controlled trials presented at the ACR Convergence 2021 virtual meeting suggest no significant benefits of treatment with the BAFF inhibitor belimumab or the heat shock response amplifier arimoclomol for patients with idiopathic inflammatory myopathy.

01-11-2021 | COVID-19 | News

COVID-19: Inactivated vaccine has ‘moderate’ immunogenicity in myopathy patients

People with systemic autoimmune myopathies have moderate seroconversion rates following two doses of the Sinovac inactivated SARS-CoV-2 vaccine, with reduced immunogenicity relative to that seen in healthy controls, researchers report.

22-10-2021 | Dermatomyositis | News

New EULAR/ACR dermatomyositis criteria shed light on disease frequency, mortality

A population-based cohort study using the 2017 EULAR/American College of Rheumatology criteria for dermatomyositis has identified a higher incidence, prevalence, and associated mortality rate than previously reported.

Antibodies (illustration)

23-09-2021 | Myositis | News

Myositis-specific autoantibodies could aid inflammatory myopathy classification

Some subgroups of patients with myositis-specific autoantibody positive inflammatory myopathies are “frequently misclassified” based on currently used criteria, and adopting an autoantibody-based system may improve classification, researchers report.

Anifrolumab for the treatment of lupus

Anifrolumab for the treatment of SLE

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

New additions to the Adis Journal Club

Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

22-07-2021 | Polymyositis | Article

Heart failure risk increased in polymyositis, dermatomyositis

People with newly-diagnosed polymyositis or dermatomyositis have a significantly higher 10-year risk for heart failure hospitalization than people who do not have these conditions, suggests research conducted in Taiwan.

22-07-2021 | Dermatomyositis | News

IVIG receives FDA approval for dermatomyositis

The US FDA has approved intravenous immunoglobulin for the treatment of dermatomyositis in adults.

03-06-2021 | EULAR 2021 | Conference coverage | News

ProDERM demonstrates benefits of IVIG in patients with dermatomyositis

Phase 3 trial results suggest that intravenous immunoglobulin may be a promising treatment option for patients with dermatomyositis.

26-05-2021 | Myositis | News

​​​​​​​Myositis linked to elevated stroke risk

People with idiopathic inflammatory myopathies may be at increased risk for ischemic stroke, suggest findings from a systematic review and meta-analysis.

ACR Convergence 2021 highlights

ACR Convergence 2021

3–9 November: Keep up with the latest news and interviews from the conference.

Febuxostat and cardiovascular risk in people with gout

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

Telemedicine in rheumatology

Telemedicine in rheumatology: COVID-19 and beyond

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.